Optimizing Surgical Decisions in Young Adults With Breast Cancer
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete…
Conditions studied
Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
About this study
The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded.
Interventions
- Other: CONSYDER decision aid — Web-based breast cancer surgery decision aid
Primary outcomes
- Pre-surgical decisional conflict as measured by the Decisional Conflict Scale (DCS) (pre-surgery)
- Use of CONSYDER pre-consult (pre-surgery)
Eligibility information
Study locations
- Yale Cancer Center, New Haven, Connecticut 06510 United States
- Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
- Weill Cornell Medicine, New York, New York 10065 United States
- Duke Cancer Institute, Durham, North Carolina 27710 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.